U.S. Markets open in 7 hrs 24 mins

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0300-0.0200 (-1.90%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®
    PR Newswire

    Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®.

  • Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
    PR Newswire

    Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has filed an amendment to its Mino-Lok phase 3 protocol. This amendment was designed to allow for more efficient follow-up and record-keeping of required clinical trial documentation given COVID-19 restrictions. With personal visits having been severely restricted, Citius issued instructions in the form of file notes to sites in April and has now formalized these instructions. The FDA released guidance on conduct of clinical trials of medical products during COVID-19 in March 2020, updated in July 2020.

  • Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference
    PR Newswire

    Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that its management is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Leonard Mazur, Chairman of Citius, will present on Tuesday, September 15, at 11:00 a.m. Eastern Time where he will deliver a corporate overview of the Company.